Harbor Health Care ETF Q4 2025 Commentary

The Harbor Health Care ETF returned 10.43% (NAV) in Q4, underperforming the Russell 3000® Growth Health Care Index which returned 16.71% — a 6.28 percentage-point shortfall. The underperformance was driven by stock selection and relative underexposure to higher-beta development-stage biotech and speculative medtech names, while an overweight to volatility was the largest factor tailwind, partially offset by an underweight to size.

Analysis

The portfolio posture implicit in recent flows favors predictability over option-like upside, which systematically undercaptures the sector’s highest-return events: binary clinical data, regulator decisions, and M&A. Those outcomes create asymmetric payoffs—single Phase 2/3 readouts or a mid-cap strategic bid can rerate a basket of development-stage names by multiples in weeks—so low-convexity positioning cedes a meaningful portion of total sector alpha.

A persistently cautious allocation also lengthens the pathway for small-cap financing: reduced secondary issuance, wider spreads on convertibles, and delayed IPO windows will raise the cost of capital for early-stage developers over the next 6–24 months. That dynamic benefits recurring-revenue service providers (CROs, CDMOs, diagnostics OEMs) and large-cap pharma that can acquire cheap pipeline assets, while pressuring suppliers of reagents and capital-intensive device startups whose breakevens depend on rapid follow‑on funding.

Key catalysts that would flip the current regime are foreseeable and time-bound: a sequence of positive pivotal readouts in hot modalities (cell/gene therapy, ADCs, AI-enabled drug discovery) over the next 3–9 months, or a credible easing in financial conditions over the same window. Downside tails include a cluster of high-profile trial failures, accelerated regulatory tightening, or a renewed risk‑off shock that reinstalls funding scarcity; each could compress small-cap valuations by another 20–40% within a quarter.

The contrarian posture to consider is selective aggression: where consensus treats development-stage biotech as a noise bucket, the market has underpriced event convexity and optionality in names with clean binary calendars and manageable cash burn. A concise, event-driven exposure with disciplined size and volatility hedges captures asymmetric upside while limiting permanent capital losses if the macro regime remains unfavorable.

Key Decisions for Investors

• Long XBI (SPDR S&P Biotech ETF) 6–12 month call spread: buy OTM call / sell further OTM call to cap cost. Time for entry ahead of clustered Phase 2/3 windows (3–9 months). R/R: pay ~10–25% of notional for 30–100% upside if XBI re-rates; max loss = premium.
• Pair trade: long XBI / short XLV (Healthcare Select Sector SPDR) sized 1:0.6 for 3–9 months to capture small-cap convexity vs defensive carry. Hedge tail with 3–6 month SPY puts sized to limit portfolio drawdown to target (e.g., 6–8% of NAV). Expect 1.5–3x asymmetric payoff if risk-on resumes; downside is correlated market selloff.
• Event-driven single-name option buys around clean binary readouts: purchase 3–9 month ATM calls (or call spreads) on development-stage names with <18 months cash runway and clearly defined data catalysts. Position size per event limited to 0.5–1% NAV; target >3x payoff on positive readout, cut losses to <100% of premium on negative outcome.
• Long selective CRO/CDMO exposure (examples: ICLR, TMO) for 12–24 months to capture secular flight-to-quality in services and potential M&A multiple expansion. Use 1–2% NAV put protection to guard against sharp risk-off; expected IRR 12–20% if small-cap funding stays constrained and deal activity accelerates.